International Journal of Hematology

, Volume 100, Issue 3, pp 296–306

Effect of graft sources on allogeneic hematopoietic stem cell transplantation outcome in adults with chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a Japanese Society of Hematopoietic Cell Transplantation retrospective analysis

  • Kazuteru Ohashi
  • Tokiko Nagamura-Inoue
  • Fumitaka Nagamura
  • Arinobu Tojo
  • Kouichi Miyamura
  • Takehiko Mori
  • Mineo Kurokawa
  • Shuichi Taniguchi
  • Jun Ishikawa
  • Yasuo Morishima
  • Yoshiko Atsuta
  • Hisashi Sakamaki
Original Article

DOI: 10.1007/s12185-014-1632-9

Cite this article as:
Ohashi, K., Nagamura-Inoue, T., Nagamura, F. et al. Int J Hematol (2014) 100: 296. doi:10.1007/s12185-014-1632-9

Abstract

We retrospectively compared transplant outcomes for related bone marrow transplantation (rBMT), related peripheral blood stem cell transplantation (rPBSCT), unrelated bone marrow transplantation (uBMT), and unrelated cord blood transplantation (CBT) in 1,062 patients with chronic myeloid leukemia (CML) aged 20 years or over between January 1, 2000 and December 31, 2009 in Japan. The disease status was as follows: chronic phase 1 (CP1, n = 531), CP 2 or later including accelerated phase (CP2-AP, n = 342) and blastic crisis (BC, n = 189). Graft sources (GS) were rBMT (n = 205), uBMT (n = 507), rPBSCT (n = 226) or CBT (n = 124). In multivariate analysis in CP1, lower overall survival (OS) (relative risk [RR]: 6.01, 95 % confidence interval [CI]: 1.20–29.97, P = 0.029) and leukemia-free survival (LFS) (RR: 4.26, 95 % CI: 1.24–14.62, P = 0.021) were observed in uBMT compared with those in rBMT. For patients in the advanced phase of CML beyond CP1, GS had no significant impact on OS or LFS. Our results support the use of rBMT for adults with CML in CP1, but in contrast to previous reports, the superiority of rPBSCT in advanced stage of CML was not confirmed in our cohorts.

Keywords

Chronic myeloid leukemiaAllogeneic hematopoietic stem cell transplantationGraft sources

Supplementary material

12185_2014_1632_MOESM1_ESM.xlsx (13 kb)
Supplementary material 1 (XLSX 13 kb)

Copyright information

© The Japanese Society of Hematology 2014

Authors and Affiliations

  • Kazuteru Ohashi
    • 1
  • Tokiko Nagamura-Inoue
    • 2
    • 12
  • Fumitaka Nagamura
    • 3
  • Arinobu Tojo
    • 4
  • Kouichi Miyamura
    • 5
  • Takehiko Mori
    • 6
  • Mineo Kurokawa
    • 7
  • Shuichi Taniguchi
    • 8
  • Jun Ishikawa
    • 9
  • Yasuo Morishima
    • 10
    • 13
  • Yoshiko Atsuta
    • 11
    • 14
  • Hisashi Sakamaki
    • 1
    • 14
  1. 1.Hematology Division, Tokyo Metropolitan Cancer and Infectious Disease CenterKomagome HospitalTokyoJapan
  2. 2.Department of Cell Processing and Transfusion, Research Hospital, The Institute of Medical ScienceThe University of TokyoTokyoJapan
  3. 3.Division of Clinical Trial Safety Management, Research Hospital, The Institute of Medical ScienceThe University of TokyoTokyoJapan
  4. 4.Department of Hematology/Oncology, Research Hospital, The Institute of Medical ScienceThe University of TokyoTokyoJapan
  5. 5.Department of HematologyJapanese Red Cross Nagoya Daiichi HospitalNagoyaJapan
  6. 6.Division of Hematology, Department of MedicineKeio University School of MedicineTokyoJapan
  7. 7.Department of Cell Therapy and Transplantation MedicineThe University of TokyoTokyoJapan
  8. 8.Department of HematologyToranomon HospitalTokyoJapan
  9. 9.Department of Hematology and ChemotherapyOsaka Medical Center for Cancer and Cardiovascular DiseasesOsakaJapan
  10. 10.Division of Epidemiology/PreventionAichi Cancer Center Research InstituteNagoyaJapan
  11. 11.Department of HSCT Data Management/BiostatisticsNagoya University Graduate School of MedicineNagoyaJapan
  12. 12.Japan Cord Blood Bank NetworkTokyoJapan
  13. 13.Japan Marrow Donor ProgramTokyoJapan
  14. 14.Japanese Society of Hematopoietic Cell TransplantationNagoyaJapan